Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time?

A pilot study using the 5-HT4 receptor agonist mosapride

Masanao Nakamura, Naoki Ohmiya, Ryoji Miyahara, Takafumi Ando, Osamu Watanabe, Hiroki Kawashima, Akihiro Itoh, Yoshiki Hirooka, Yasumasa Niwa, Hidemi Goto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Backgrounds/Aims: A prospective correlation study of symptomatic changes due to administration of prokinetic drugs and changes of transit time of capsule endoscopy (CE), for patients with constipation-predominant irritable bowel syndrome (IBS-C), and examination of usefulness of CE in the objective evaluation of IBS-C. Methodology: Mosapride citrate was administered to ten subjects and CE transit evaluated together with a symptom questionnaire before and after administration. Frequency and severity of abdominal pain, times of defecation and Bristol stool scales were listed and scored. Primary and secondary endpoints were the correlation between symptomatic changes due to the administration and changes of CE transit and the effect of mosapride citrate on IBS-C, CE findings, and gastric and small bowel transit time (GTT, SBTT). Results: After administration for 4 weeks, the mean scores of evaluated symptoms all improved. GTT was not significantly changed, but SBTT showed significant shortening post-administration (p=0.02). In only one patient's CE, three small erosions were detected. The changes in the times of defecation before and after the administration were significantly correlated with those in the SBTT of CE (R=0.888, p=0.0006). However, other symptoms were not significantly correlated with SBTT. Conclusions: CE transit correlated with intestinal motility in symptomatic changes and could be a possible index for the objective assessment of motility in IBS-C.

Original languageEnglish
Pages (from-to)453-458
Number of pages6
JournalHepato-Gastroenterology
Volume58
Issue number106
Publication statusPublished - 01-03-2011
Externally publishedYes

Fingerprint

Serotonin 5-HT4 Receptor Agonists
Receptors, Serotonin, 5-HT4
Capsule Endoscopy
Irritable Bowel Syndrome
Defecation
Gastrointestinal Motility
mosapride
Constipation
Abdominal Pain
Stomach
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Hepatology

Cite this

Nakamura, Masanao ; Ohmiya, Naoki ; Miyahara, Ryoji ; Ando, Takafumi ; Watanabe, Osamu ; Kawashima, Hiroki ; Itoh, Akihiro ; Hirooka, Yoshiki ; Niwa, Yasumasa ; Goto, Hidemi. / Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride. In: Hepato-Gastroenterology. 2011 ; Vol. 58, No. 106. pp. 453-458.
@article{26257c01e124421f8efb454bbc7ebb3b,
title = "Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time?: A pilot study using the 5-HT4 receptor agonist mosapride",
abstract = "Backgrounds/Aims: A prospective correlation study of symptomatic changes due to administration of prokinetic drugs and changes of transit time of capsule endoscopy (CE), for patients with constipation-predominant irritable bowel syndrome (IBS-C), and examination of usefulness of CE in the objective evaluation of IBS-C. Methodology: Mosapride citrate was administered to ten subjects and CE transit evaluated together with a symptom questionnaire before and after administration. Frequency and severity of abdominal pain, times of defecation and Bristol stool scales were listed and scored. Primary and secondary endpoints were the correlation between symptomatic changes due to the administration and changes of CE transit and the effect of mosapride citrate on IBS-C, CE findings, and gastric and small bowel transit time (GTT, SBTT). Results: After administration for 4 weeks, the mean scores of evaluated symptoms all improved. GTT was not significantly changed, but SBTT showed significant shortening post-administration (p=0.02). In only one patient's CE, three small erosions were detected. The changes in the times of defecation before and after the administration were significantly correlated with those in the SBTT of CE (R=0.888, p=0.0006). However, other symptoms were not significantly correlated with SBTT. Conclusions: CE transit correlated with intestinal motility in symptomatic changes and could be a possible index for the objective assessment of motility in IBS-C.",
author = "Masanao Nakamura and Naoki Ohmiya and Ryoji Miyahara and Takafumi Ando and Osamu Watanabe and Hiroki Kawashima and Akihiro Itoh and Yoshiki Hirooka and Yasumasa Niwa and Hidemi Goto",
year = "2011",
month = "3",
day = "1",
language = "English",
volume = "58",
pages = "453--458",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "106",

}

Nakamura, M, Ohmiya, N, Miyahara, R, Ando, T, Watanabe, O, Kawashima, H, Itoh, A, Hirooka, Y, Niwa, Y & Goto, H 2011, 'Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride', Hepato-Gastroenterology, vol. 58, no. 106, pp. 453-458.

Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride. / Nakamura, Masanao; Ohmiya, Naoki; Miyahara, Ryoji; Ando, Takafumi; Watanabe, Osamu; Kawashima, Hiroki; Itoh, Akihiro; Hirooka, Yoshiki; Niwa, Yasumasa; Goto, Hidemi.

In: Hepato-Gastroenterology, Vol. 58, No. 106, 01.03.2011, p. 453-458.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time?

T2 - A pilot study using the 5-HT4 receptor agonist mosapride

AU - Nakamura, Masanao

AU - Ohmiya, Naoki

AU - Miyahara, Ryoji

AU - Ando, Takafumi

AU - Watanabe, Osamu

AU - Kawashima, Hiroki

AU - Itoh, Akihiro

AU - Hirooka, Yoshiki

AU - Niwa, Yasumasa

AU - Goto, Hidemi

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Backgrounds/Aims: A prospective correlation study of symptomatic changes due to administration of prokinetic drugs and changes of transit time of capsule endoscopy (CE), for patients with constipation-predominant irritable bowel syndrome (IBS-C), and examination of usefulness of CE in the objective evaluation of IBS-C. Methodology: Mosapride citrate was administered to ten subjects and CE transit evaluated together with a symptom questionnaire before and after administration. Frequency and severity of abdominal pain, times of defecation and Bristol stool scales were listed and scored. Primary and secondary endpoints were the correlation between symptomatic changes due to the administration and changes of CE transit and the effect of mosapride citrate on IBS-C, CE findings, and gastric and small bowel transit time (GTT, SBTT). Results: After administration for 4 weeks, the mean scores of evaluated symptoms all improved. GTT was not significantly changed, but SBTT showed significant shortening post-administration (p=0.02). In only one patient's CE, three small erosions were detected. The changes in the times of defecation before and after the administration were significantly correlated with those in the SBTT of CE (R=0.888, p=0.0006). However, other symptoms were not significantly correlated with SBTT. Conclusions: CE transit correlated with intestinal motility in symptomatic changes and could be a possible index for the objective assessment of motility in IBS-C.

AB - Backgrounds/Aims: A prospective correlation study of symptomatic changes due to administration of prokinetic drugs and changes of transit time of capsule endoscopy (CE), for patients with constipation-predominant irritable bowel syndrome (IBS-C), and examination of usefulness of CE in the objective evaluation of IBS-C. Methodology: Mosapride citrate was administered to ten subjects and CE transit evaluated together with a symptom questionnaire before and after administration. Frequency and severity of abdominal pain, times of defecation and Bristol stool scales were listed and scored. Primary and secondary endpoints were the correlation between symptomatic changes due to the administration and changes of CE transit and the effect of mosapride citrate on IBS-C, CE findings, and gastric and small bowel transit time (GTT, SBTT). Results: After administration for 4 weeks, the mean scores of evaluated symptoms all improved. GTT was not significantly changed, but SBTT showed significant shortening post-administration (p=0.02). In only one patient's CE, three small erosions were detected. The changes in the times of defecation before and after the administration were significantly correlated with those in the SBTT of CE (R=0.888, p=0.0006). However, other symptoms were not significantly correlated with SBTT. Conclusions: CE transit correlated with intestinal motility in symptomatic changes and could be a possible index for the objective assessment of motility in IBS-C.

UR - http://www.scopus.com/inward/record.url?scp=79958172971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958172971&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 453

EP - 458

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 106

ER -